Nephro Care (NEPHROCARE)

Score breakdown: P/E: 0/3 · ROCE: 0/2 · Growth: 0/2 · Dividend: 0/1

Key Financials

Strengths

• Promoter holding of 61.71% shows strong insider alignment with minority shareholders.
• ROCE of 11.27% is positive, indicating the existing capital base generates some return.
• Current price is 54% below the 52-week high of ₹183, reflecting a steep de-rating.
• Latest quarter sales of ₹23 Cr imply an annualised run-rate of about ₹92 Cr, making the ₹127 Cr market cap roughly 1.4x sales — not stretched if profitability returns.

Concerns

• P/E of 37.37 sits on top of 0.00% profit growth and a latest quarter net profit of ₹0 Cr; valuation assumes a recovery that is not yet visible.
• Piotroski F-Score of 3/9 suggests weak financial health and poor operating efficiency.
• Zero dividend yield means shareholders get no income while waiting for the story to improve.
• No book value, debt/equity, or ROE data makes it impossible to assess the balance sheet or margin of safety, which is a basic Graham requirement.

AI Analysis

Let me look at Nephro Care through a Graham-Buffett lens. At ₹85, the market cap is ₹127 crore, but the P/E is 37.37. That is a steep price for a business showing 0.00% sales growth and 0.00% profit growth. The latest quarter tells a bleaker story: sales of ₹23 crore and net profit of ₹0 crore. I cannot value a business on hope; I need demonstrated earning power. The Piotroski F-score of 3/9 reinforces my caution — this is a weak signal on financial and operating health. Return on capital employed is 11.27%, which is respectable but hardly a fortress. I have no book value, debt/equity, or ROE data, so I cannot gauge the balance sheet's margin of safety. Without that, I feel like I am buying a sack without knowing its contents. On the positive side, promoters hold 61.71%, so their interests are tied to mine, and at ₹85 the stock is 54% below its 52-week high of ₹183. But a falling price is not by itself value; in Benjamin Graham's words, the market is a pendulum, not a voting machine, and I do not want to catch a falling knife. The zero dividend means I get no income while waiting. This is not a standard Buffett 'wonderful business at a fair price'. It is a small hospital business that appears to be struggling to convert revenue into profit. If the latest quarter's run-rate sales of roughly ₹92 crore are maintained, the price-to-sales ratio is modest, but profits matter most. I would need proof of sustainable margin recovery and a clean balance sheet before considering it. For now, this remains a turnaround speculation, not an investment.

Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer